Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Documentation/Oscar, Milestone.....
15
Jul 23, 2010 07:49AM
10
Jul 23, 2010 08:47AM
2
Jul 23, 2010 09:10AM
8
Jul 23, 2010 10:05AM
8
Jul 23, 2010 10:19AM
10
Jul 23, 2010 10:30AM
4
Jul 23, 2010 11:17AM

I hope the extract below will answer your question and also address any specious concerns about Leckrone discussing the MMP Portfolio at Shareholder Meetings, instead of the BoD:

7.6 Public Announcements. From the date hereof until the earlier of the Termination Date or the termination of the Commercialization Agreement, TPL and Patriot agree to consult with each other before (a) issuing any press release,
(b) making any public statement with respect to this Agreement or the transactions contemplated hereby (including, without limitation, with respect to the consideration to be paid pursuant to this Agreement or any license agreement pursuant to the Commercialization Agreement),

As can be readily seen, to remain in compliance with the Agreement it was far easier to allow Leckrone the floor on all matters MMP Portfolio.

Unless, it is being suggested that the BoD and Leckrone should have consulted with each other during the meeting, and upon a mutually agreeable response, returned to the meeting for a BoD member to give the reply?

.

.

.

Be well

Share
New Message
Please login to post a reply